X0202 SCHEDULE 13G/A 0000902664-25-000983 0001910456 XXXXXXXX LIVE 1 Common Stock, par value $0.001 per share 12/31/2025 0001737287 Allogene Therapeutics, Inc. 019770106 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 Rule 13d-1(c) Lynx1 Capital Management LP DE 0.00 0.00 0.00 0.00 0.00 N 0 PN Weston Nichols X1 0.00 0.00 0.00 0.00 0.00 N 0 IN Allogene Therapeutics, Inc. 210 East Grand Avenue, South San Francisco, California 94080 This statement is filed by: (i) Lynx1 Capital Management LP (the "Investment Manager"), a Delaware limited partnership, and the investment manager to Lynx1 Master Fund LP (the "Lynx1 Fund"), with respect to the shares of common stock, par value $0.001 per share ("Common Stock"), of Allogene Therapeutics, Inc., a Delaware corporation, that were directly held by the Lynx1 Fund; and (ii) Mr. Weston Nichols ("Mr. Nichols"), the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager, with respect to the shares of Common Stock that were directly held by the Lynx1 Fund. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein. Lynx1 Capital Management LP D81 Calle C Suite 301, PMB 1202 Dorado, PR, 00646-2051 Weston Nichols c/o Lynx1 Capital Management LP D81 Calle C Suite 301, PMB 1202 Dorado, PR, 00646-2051 Investment Manager - Delaware Mr. Nichols - United States of America Y The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. 0% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Lynx1 Capital Management LP /s/ Weston Nichols 05/15/2026 Weston Nichols /s/ Weston Nichols 05/15/2026